H.C. Wainwright analyst Andres Maldonado raised the firm’s price target on Scholar Rock (SRRK) to $50 from $40 and keeps a Buy rating on the shares. The firm says the “mixed signals” from Biohaven’s (BHVN) Phase 3 taldefgrobep alfa data are a net positive for Scholar Rock’s apitegromab’s penetration dynamics. The firm now views the launch trajectory for apitegromab “as clear of any near-term headwinds.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRRK:
- Macy’s uncovers employee fraud, Summit to be acquired: Morning Buzz
- Biohaven outcome ‘fundamental net positive’ for Scholar Rock, says JPMorgan
- Truist ups Scholar Rock targets, calls potential takeout target
- Scholar Rock ‘easier to own’ after Biohaven data, says Jefferies
- Scholar Rock up after Biohaven SMA data disappoints